Secondary neoplasms in malignant lymphomas after intensive therapy.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008545:Melanoma / Q000209:etiology; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced / Q000209:etiology*; D009381:Neoplasms, Radiation-Induced; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies
D000970:Antineoplastic Agents; D011344:Procarbazine